BRAFV600Epositivity is associated with increased aggressiveness of papillary thyroid cancer (PTC), and age is an important prognostic factor. However, the association between age and BRAFV600Epositivity and the recurrence risk has not been investigated. This study aimed to investigate the impact of age on recurrence between patients with BRAFV600E-positive and -negative PTC. Patients with PTC who underwent initial thyroid surgery between January 2010 and December 2018 at Seoul St. Mary’s Hospital (Seoul, Republic of Korea) were retrospectively reviewed. The BRAFV600E-positive (n= 1768) and BRAFV600E-negative groups (n= 428) were divided into two subgroups: younger (<35 years) and older groups (≥55 years). In the BRAFV600E-positive group, the younger group exhibited higher lymphatic and vascular invasion rates, more positive lymph nodes, higher lymph node ratios, and higher recurrence rates than the older group (5.9% vs. 2.1%). Multivariate analysis revealed that age, lymphatic invasion, and N category were significant risk factors in the BRAFV600E-positive group. In the BRAFV600E-positive group, the younger group had a higher recurrence risk than the older group (OR, 2.528; 95% confidence interval, 1.443–4.430;p= 0.001). In the BRAFV600E-negative group, age had no impact on recurrence risk. These results contribute to tailored treatment strategies and informed patient management.
BRAFV600E阳性与甲状腺乳头状癌（PTC）侵袭性增强相关，而年龄是重要的预后因素。然而，年龄与BRAFV600E阳性状态及复发风险之间的关联尚未得到充分研究。本研究旨在探讨年龄对BRAFV600E阳性和阴性PTC患者复发风险的影响。研究回顾性分析了2010年1月至2018年12月期间在首尔圣母医院（韩国首尔）接受初次甲状腺手术的PTC患者。将BRAFV600E阳性组（n=1768）和阴性组（n=428）分别划分为年轻亚组（<35岁）与年长亚组（≥55岁）。在BRAFV600E阳性组中，年轻亚组相较于年长亚组表现出更高的淋巴管和血管侵犯率、更多淋巴结阳性数、更高的淋巴结转移率及更高的复发率（5.9% vs. 2.1%）。多变量分析显示，在BRAFV600E阳性组中，年龄、淋巴管侵犯和N分期是显著的复发风险因素。该组年轻患者的复发风险显著高于年长患者（OR=2.528；95%置信区间1.443–4.430；p=0.001）。而在BRAFV600E阴性组中，年龄对复发风险无显著影响。这些研究结果有助于制定个体化治疗策略并优化患者管理方案。
BRAFV600EPositivity-Dependent Effect of Age on Papillary Thyroid Cancer Recurrence Risk
肿瘤(癌症)患者之家